Bukwang Pharmaceutical   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Seoul Korea, Republic of (1960)

Organization Overview

First Clinical Trial
2002
NCT00305019
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Bukwang Pharmaceutical | Bukwang Pharmaceutical, Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 4)

Carcinoma, Hepatocellular (Phase 4)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Diabetic Neuropathies (Phase 3)

Dyskinesia, Drug-Induced (Phase 2)

Dyskinesias (Phase 2)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hepatitis C (Phase 3)

Hepatitis, Chronic (Phase 4)

Irritable Bowel Syndrome (Phase 4)

Mental Disorders (Phase 3)

Parkinson Disease (Phase 2)

Psychotic Disorders (Phase 3)

Schizophrenia (Phase 3)

Spinal Cord Injuries (Phase 1)

Stomach Neoplasms (Phase 1)

Syndrome (Phase 4)

Wounds and Injuries (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 37
  • # of Trial APIs: 19